Experts Spotlight ASH 2025 Data Poised to Change Treatment Paradigms in AML, MZL, and Myeloma

Among the myriad of data presented during the 2025 ASH Annual Meeting and Exposition, several studies signaled a clear departure from long-standing treatment norms, according to experts. These presentations underscored meaningful shifts in the management of several hematologic malignancies, particularly with respect to the role of low-intensity regimens in acute myeloid leukemia (AML), expanded applications for CAR T-cell therapy in marginal zone lymphoma (MZL), and the potential for bispecific antibodies to redefine standards of care in multiple myeloma in both the relapsed/refractory and frontline settings.